44 related articles for article (PubMed ID: 26210682)
21. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
[TBL] [Abstract][Full Text] [Related]
22. Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives.
Fang Y; Liao G; Yu B
Acta Pharm Sin B; 2020 Jul; 10(7):1253-1278. PubMed ID: 32874827
[TBL] [Abstract][Full Text] [Related]
23. Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction.
Rasafar N; Barzegar A; Mehdizadeh Aghdam E
Sci Rep; 2020 Jul; 10(1):11449. PubMed ID: 32651397
[TBL] [Abstract][Full Text] [Related]
24. Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.
Li W; Peng X; Lang J; Xu C
Front Pharmacol; 2020; 11():631. PubMed ID: 32477121
[TBL] [Abstract][Full Text] [Related]
25. Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry.
Ghosh AK; Brindisi M
J Med Chem; 2020 Mar; 63(6):2751-2788. PubMed ID: 31789518
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Approaches Targeting Nucleolus in Cancer.
Carotenuto P; Pecoraro A; Palma G; Russo G; Russo A
Cells; 2019 Sep; 8(9):. PubMed ID: 31527430
[TBL] [Abstract][Full Text] [Related]
27. The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma.
Hsieh CC; Shen CH
Curr Treat Options Oncol; 2019 Feb; 20(3):22. PubMed ID: 30778775
[TBL] [Abstract][Full Text] [Related]
28. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in
Stolte B; Iniguez AB; Dharia NV; Robichaud AL; Conway AS; Morgan AM; Alexe G; Schauer NJ; Liu X; Bird GH; Tsherniak A; Vazquez F; Buhrlage SJ; Walensky LD; Stegmaier K
J Exp Med; 2018 Aug; 215(8):2137-2155. PubMed ID: 30045945
[TBL] [Abstract][Full Text] [Related]
29. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
30. Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.
McNally JP; Millen SH; Chaturvedi V; Lakes N; Terrell CE; Elfers EE; Carroll KR; Hogan SP; Andreassen PR; Kanter J; Allen CE; Henry MM; Greenberg JN; Ladisch S; Hermiston ML; Joyce M; Hildeman DA; Katz JD; Jordan MB
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):E4782-E4791. PubMed ID: 28533414
[TBL] [Abstract][Full Text] [Related]
31. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
32. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.
Higgins B; Glenn K; Walz A; Tovar C; Filipovic Z; Hussain S; Lee E; Kolinsky K; Tannu S; Adames V; Garrido R; Linn M; Meille C; Heimbrook D; Vassilev L; Packman K
Clin Cancer Res; 2014 Jul; 20(14):3742-52. PubMed ID: 24812409
[TBL] [Abstract][Full Text] [Related]
33. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
Andreeff M; Kelly KR; Yee K; Assouline S; Strair R; Popplewell L; Bowen D; Martinelli G; Drummond MW; Vyas P; Kirschbaum M; Iyer SP; Ruvolo V; González GM; Huang X; Chen G; Graves B; Blotner S; Bridge P; Jukofsky L; Middleton S; Reckner M; Rueger R; Zhi J; Nichols G; Kojima K
Clin Cancer Res; 2016 Feb; 22(4):868-76. PubMed ID: 26459177
[TBL] [Abstract][Full Text] [Related]
34. Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis.
Iancu-Rubin C; Mosoyan G; Glenn K; Gordon RE; Nichols GL; Hoffman R
Exp Hematol; 2014 Feb; 42(2):137-45.e5. PubMed ID: 24309210
[TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
Patnaik A; Tolcher A; Beeram M; Nemunaitis J; Weiss GJ; Bhalla K; Agrawal M; Nichols G; Middleton S; Beryozkina A; Sarapa N; Peck R; Zhi J
Cancer Chemother Pharmacol; 2015 Sep; 76(3):587-95. PubMed ID: 26210682
[TBL] [Abstract][Full Text] [Related]
36. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
[TBL] [Abstract][Full Text] [Related]
37. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]